China Isotope & Radiation Corp. 1763

BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its investigational gene therapy, rebisufligene etisparvovec, for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A. EMA validation confirms that the application is sufficiently complete for the Agency to begin its formal scientific review. Validation

LUXEMBOURG, October 02, 2026--Regulatory News: Eurofins Scientific SE (Paris:ERF) (the "Company" or "Eurofins") (EUFI.PA) announces the completion of the divestment of its Electrical & Electronic Testing business ("MET Labs") to UL Solutions Inc., which took place on 1 October 2026. The transaction was announced on 14 April 2026 for an Enterprise Value of €575 million on a cash and debt free basis.

LUXEMBOURG, October 02, 2026--Regulatory News: Eurofins Scientific (EUFI.PA) (Paris:ERF), a global scientific leader in bioanalytical testing, announces the successful closing of its acquisition of the Life Sciences Testing Services business in North America of Element Materials Technology ("Element"), which took place on 1 October 2026. The transaction was announced on 20 July 2026 for an enterprise value of USD400m.

Green Thumb Industries (CNSX:GTII) has moved back into focus after management approved a US$50 million share repurchase program, adding a capital allocation twist to a sector that is already dealing with renewed regulatory uncertainty. Price action tells the story. Green Thumb Industries has a 1-day share price return of 3.4% after the buyback news, while the 7-day and 90-day share price returns are down 12.0% and 10.5% as regulatory delays and sector-wide caution continue to weigh on...

The analyst fair value estimate for Lexicon Pharmaceuticals has shifted from US$3.77 to US$4.55 per share, reflecting a higher modeled upside in the latest work. Recent Street commentary links this move to growing focus on sotagliflozin and the fully enrolled Phase 3 SONATA HCM trial, which has a defined data readout in 1Q27. As you read on, you will see how these factors shape the evolving Lexicon Pharmaceuticals story and what to watch as the narrative develops. Stay updated as the Fair...

Jean-Philippe Rocher Appointed Head of Pharmaceutical DevelopmentMikhail Kalinichev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 2, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment of Jean-Philippe Rocher as Head of Pharmaceutical Development and

TOULOUSE, France & FULLERTON, Calif., October 02, 2026--Regulatory News: ABIONYX Pharma (FR0012616852 – ABNX – eligible for PEA-PME) ("Abionyx" or the "Company"), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on its exclusive apoA-I technology platform, today announces (i) a partial repayment of the principal amount of the bonds subscribed by Fenja Capital II A/S ("Fenja") and (ii) consequently, the pricing of a EUR 0.52 Million res

Abogen Biosciences ("Abogen" or the "Group"), a clinical-stage biotechnology group pioneering RNA innovation, announced that it has entered into a licensing and option agreement with Novartis to advance RNA-encoded therapeutics. The agreement includes an exclusive worldwide license to Abogen's lead asset, ABO2203, as well as options to exclusively license other potential programs leveraging Abogen's proprietary RNA platform.

Twist Bioscience has turned into one of the market’s stronger long term performers, and the latest surge leaves a simple but important question on the table. Do the company’s current cash flows and their future potential really support today’s share price around US$188? Over the past 3 years, Twist Bioscience has delivered a gain of about 9x, which puts a lot of pressure on its cash flows to justify how far the stock has already run. The new collaboration with Eli Lilly’s TuneLab ties Twist...

A longer shortage seems like great news for the flash memory specialist. Why did the stock hardly move?

Global bond markets have been hit hard recently, with the UK 30-year gilt yield touching 6%, which is the highest level since 1998. Higher borrowing costs can pressure many sectors, but they often push investors toward businesses seen as essential. In Britain, healthcare is one example. This article highlights three leading UK healthcare stocks from our quality-focused screener that some investors use as a potential anchor in turbulent markets. The stocks covered below are a sample from this...

Zoetis Inc. (NYSE:ZTS) has built one of the strongest franchises in animal health. Its products are used by veterinarians around the world; its portfolio spans medicines, vaccines, and diagnostics, and its research capabilities have helped establish entire categories of treatment. But a moat is only valuable if it protects market share and pricing power when […]

Gilead shares are up 35% since Barron’s highlighted them, but our catalysts have yet to fully play out.

Angelalign Technology Inc. (6699.HK) ("Angel") http://www.angelaligner.com, a global trailblazer in orthodontic clear aligner technology, today announced the launch of Pressure Points in the European market, an upgraded feature that replaces the company's current Torque Ridges. The upgrade reflects Angel's continued commitment to innovation focused on solving orthodontists' clinical challenges.

Treasuries pay more today, but these three healthcare dividend payers offer something Treasuries can't: growth in both the payout and the stock.

AstraZeneca PLC (NASDAQ:AZN) said on September 28 that it will make a $2 billion equity investment in Summit Therapeutics, Inc. (NASDAQ:SMMT) and run joint trials of the two companies’ cancer drugs. The money buys preferred shares convertible into common stock at an equivalent of $18.36 each, a premium to Summit’s September 28 close of $15.48. […]

Align Technology (NasdaqGS:ALGN) has been highlighted as a key participant in new reports on the global dental equipment market. Researchers cite emerging demand for digital dentistry tools and cosmetic treatments as major drivers in these market assessments. The reports position Align Technology alongside other dental equipment suppliers as exposure to these themes attracts fresh investor attention. Align being profiled as a major player in dental equipment growth is useful context, but not...